MedTrace Logo

Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01

NCT05897957 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2024-04-12

No results posted yet for this study

Summary

This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No investigational therapy will be administered in this study.

Conditions

  • Parkinson Disease

Sponsors & Collaborators

  • BlueRock Therapeutics

    lead INDUSTRY

Principal Investigators

  • Nauman Abid, MD · BlueRock Therapeutics LP

Eligibility

Min Age
50 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-16
Primary Completion
2027-05-31
Completion
2027-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05897957 on ClinicalTrials.gov